Q-omics provides the consensus-scored AMD1P4 profile across patient tissues and cancer cell-line models. AMD1P4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, AMD1P4 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, AMD1P4 RNA expression shows 13,674 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LIHC, and TGCT as cancer lineages where AMD1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMD1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMD1P4 survival associations across molecular data types. AMD1P4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMD1P4 RNA expression–survival associations across cancer types. High AMD1P4 expression shows unfavorable associations in UCEC, KIRP, ACC and COAD, but favorable associations in LIHC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for AMD1P4 RNA expression.
This table summarizes AMD1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for AMD1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMD1P4 shows lower tumor expression in LIHC, CHOL and LUAD and higher tumor expression in KIRC and LUAD. The LIHC box plot shows higher AMD1P4 RNA expression in normal versus tumor tissue (log2 FC = −1.547, t-test p < 0.001).
This table shows molecular features associated with AMD1P4 in patient tissues and cancer cell lines. In patient samples, AMD1P4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
